Products & ReviewDrug discovery > Pre-Clinical Development
OrganoidXplore
OrganoidXplore™, Organoid Panel Screening Service
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Description
Features and Purpose: This screening service enables the thorough examination of a wide range of cancer models, anchored by a comprehensive library of Patient-Derived Organoid (PDO) and Patient-Derived Xenograft Organoid (PDXO) models with detailed mutational landscapes.
It offers a systematic approach to quantifying drug effects on both tumor and normal tissue organoids, enhancing the understanding of therapeutic impacts.
Features or Benefits:
- Measure tumor drug response in both tumor and normal organoids
- Explore new indications with validated targets
- Benefit from inclusion of 9 normal models, including 7 matched normal/disease pairs for comprehensive analysis
- Access 100+ well-characterized PDO and PDXO models for enhanced precision
- Representing clinically relevant mutational profiles, including KRAS, BRAF, BRCA 1 and 2, and EGFR
- Quantify cell viability and explore potential drug combinations
Applications:
- Fast-track your oncology drug development with results from 100+ models
- Identify your lead compound(s), stratify patients into responders, partial responders, and non-responders or preselect models for follow up studies in vitro/in vivo.
